Status:
RECRUITING
Treatment of Nosebleeds in the Emergency Department With Powder Tranexamic Acid
Lead Sponsor:
Dr. Anne Conlin
Collaborating Sponsors:
University of Ottawa
Conditions:
Epistaxis Nosebleed
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Nosebleeds are very common, occurring in 60% of the population; in some patients, nosebleeds are a life-threatening emergency. To stop a nosebleed in the emergency department, doctors usually have to ...
Eligibility Criteria
Inclusion
- Capable of giving informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Adults 18 years or older
- Male or female
- Presenting to the ED with active, spontaneous epistaxis. Anterior versus posterior epistaxis will be identified a priori. Anterior epistaxis is operationally defined as active nasal bleeding that occurs anterior to the anterior limit of the middle turbinate, visible by anterior rhinoscopy.
Exclusion
- Prior sinonasal surgery within the preceding 1 month.
- Patients who required medical treatment for epistaxis in the preceding 30 days.
- Septum perforation.
- Known history of bleeding disorders, including thrombocytopenia, hemophilia, hereditary hemorrhagic telangiectasia, or von Willebrand disease.
- History of known thromboembolic disease, including subarachnoid hemorrhage, stroke, or TIA.
- Known history of disease of the central nervous system, including seizures, convulsions, or intra-cerebral disease processes/lesions.
- Known or suspected history of significant skull base trauma, including skull base fracture or cerebrospinal fluid leak.
- Known history of acquired disturbances of colour vision.
- Known hematuria or any bleeding related to the kidney.
- Pregnant and/or lactating women.
- History of known allergy or sensitivity to the study medication.
- Presence of signs or symptoms of concomitant emergent conditions, including myocardial infarction, stroke, major trauma, shock, or hemodynamic instability.
- Patients with other medical conditions including cognitive limitations or impairment due to substance abuse.
- Patients with any other condition that, in the opinion of the investigator, may present an unreasonable risk to the patient, may make the patient unreliable, or may interfere with the study assessments.
- Current participation in another interventional clinical trial.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06997796
Start Date
May 1 2025
End Date
December 1 2025
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peterborough Regional Health Centre
Peterborough, Ontario, Canada, K9J 7C6